ArticleScientific reports2018
Epigenetic modulator UVI5008 inhibits MRSA by interfering with bacterial gyrase.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 33 citations in OpenAlex.
- Dual Mechanisms of Action of a Halogenated Allyl Fatty Acid against Methicillin-ResistantACS omega · 2025Article
- Different aspects of Pseudomonas aeruginosa biofilm: an in-depth analysis from formation to detection.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Novel Insights into the Nobilamide Family from a Deep-SeaMarine drugs · 2025Article
- Probing Antibacterial and Anticancer Potential ofMolecules (Basel, Switzerland) · 2023Article
- New Imidazolium Alkaloids with Broad Spectrum of Action from the Marine BacteriumPharmaceutics · 2023Article
- Evaluation of Antimicrobial Properties and Potential Applications ofPharmaceutics · 2023Article
- Antimicrobial resistance and mechanisms of epigenetic regulation.Frontiers in cellular and infection microbiology · 2023Review
- Antibiotic Resistance Profiling of PathogenicBioMed research international · 2023Article
- Identification of a Transmembrane Protein Involved in Shear Stress Signaling and Hepatocarcinogenesis After a Sustained Virological Response to Hepatitis C Virus.Cellular and molecular gastroenterology and hepatology · 2023Article
- Synergistic Antitumoral Effect of Epigenetic Inhibitors and Gemcitabine in Pancreatic Cancer Cells.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Epigenetic-Mediated Antimicrobial Resistance: Host versus Pathogen Epigenetic Alterations.Antibiotics (Basel, Switzerland) · 2022Review
- Niclosamide as a Repurposing Drug againstAntibiotics (Basel, Switzerland) · 2022Article
- Trend of Bacterial Uropathogens and Their Susceptibility Pattern: Study of Single Academic High-Volume Center in Italy (2015-2019).International journal of microbiology · 2021Article
- Evaluation of Antibiotic Resistance and Biofilm Production among Clinical Strain Isolated from Medical Devices.International journal of microbiology · 2021Article
- Methicillin-resistantPathogens and global health · 2020Article
- Clinical epigenetics and multidrug-resistant bacterial infections: host remodelling in critical illness.Epigenetics · 2020Review
- Current Evidence on the Ocular Surface Microbiota and Related Diseases.Microorganisms · 2020Review
- Review
- Prevalence and Antimicrobial Susceptibility Patterns of Bacterial Pathogens in Urinary Tract Infections in University Hospital of Campania "Luigi Vanvitelli" between 2017 and 2018.Antibiotics (Basel, Switzerland) · 2020Article
- Marine-Derived Natural Lead Compound Disulfide-Linked Dimer Psammaplin A: Biological Activity and Structural Modification.Marine drugs · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The impact of multi-drug resistant bacterial strains on human health is reaching worrisome levels. Over 2 million people are infected by resistant bacteria, and more than 700,000 people die each year because of the continuous spread of resistant strains. The development of new antibiotics and the prudent use of existing ones to prolong their lifespan require a constant effort by drug industries and healthcare workers. The re-purposing of existing drugs for use as antimicrobial agents would streamline the development of new antibacterial strategies. As part of this effort, we screened a panel of drugs previously characterized to be epigenetic modulators/pro-apoptotic/differentiative drugs. We selected a few compounds that alter Gram-positive growth. Among these, UVI5008, a derivative of the natural compound psammaplin A (Psa_A), was identified. The interaction of Psa_A with the DNA gyrase enzyme has been shown, and here, we hypothesized and confirmed the gyrase-specific activity by biochemical assays. UVI5008 exhibited growth inhibition activity against Staphylococcus aureus via structural modification of the cell wall, which was observed by SEM electron microscopy. Based on our findings, we propose UVI5008 as an alternative antibacterial compound against methicillin-resistant (Met.R) S. aureus strains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.